Standards for MRI reporting—the evolution to PI-RADS v 2.0

Prostate cancer (PCa) remains a leading cause of death in the United States, but the vast majority of men diagnosed with PCa will die from other causes. While historically the capability of assessing the risk of life-threatening versus indolent PCa has relied heavily on serum prostate-specific antigen (PSA) and transrectal ultrasound (TRUS), multiparametric magnetic resonance imaging (mpMRI) has emerged as the leading tool for detection and characterization of clinically significant PCa. However, wide variations and lack of standardization of mpMRI data acquisition, interpretation, and reporting have hampered its progress. The development of a set of consensus guidelines, initially called Prostate Imaging and Reporting and Data System (PI-RADS) and eventually updated to a document called PI-RADS v2 has attempted to solve these shortcomings. As it stands, PI-RADS v2 currently represents the most up-to-date information on how to acquire, interpret, and report mpMRI of the prostate.